key: cord-0327861-g18jkvo9 authors: Padma, M. R.; Dinesh, P.; Sundaresan, R.; Athreya, S.; Shiju, S.; Maroor, P. S.; Hande, R. L.; Akhtar, J.; Chandra, T.; Ravi, D.; Lobo, E.; Ana, Y.; Shriyan, P.; Desai, A.; Rangaiah, A.; Munivenkatappa, A.; S, K.; Gowdara Basawarajappa, S.; Sreedhara, H. G.; KC, S.; Kumari B, A.; Umar, N.; BA, M.; KM, M.; Sudarshan, M. K.; Vasanthapuram, R.; Babu, G. R. title: Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India date: 2021-08-11 journal: nan DOI: 10.1101/2021.08.10.21261842 sha: 2856a21dbd4f68cfc602586ddc9ea476533fe921 doc_id: 327861 cord_uid: g18jkvo9 Objective: The second round of the serial cross sectional sentinel based population survey to assess active infection, seroprevalence, and their evolution in the general population across Karnataka was conducted. Additionally, a longitudinal study among participants identified as COVID 19 positive in the first survey round was conducted to assess the clinical sensitivity of the testing kit used. Methods: The cross sectional study of 41,228 participants across 290 healthcare facilities in all 30 districts of Karnataka was done among three groups of participants (low, moderate, and high risk). Consenting participants were subjected to real time reverse transcription polymerase chain reaction (RTPCR) testing, and antibody (IgG) testing. Results: Overall weighted adjusted seroprevalence of IgG was 15.6% (95% CI: 14.9 to 16.3), crude IgG prevalence was 15.0% and crude active prevalence was 0.5%. Statewide infection fatality rate (IFR) was estimated as 0.11%, and COVID 19 burden estimated between 26.1 to 37.7% (at 90% confidence). Clinical sensitivity of the IgG ELISA test kit was estimated as equal or more than 38.9%. Conclusion: The sentinel based population survey helped identify districts that needed better testing, reporting, and clinical management. The state was far from attaining natural immunity during the survey and hence must step up vaccination coverage and enforce public health measures to prevent the spread of COVD 19. The COVID-19 pandemic has spread globally and affected 2.58% of the population, with a case fatality rate of 2.12% as of 4 August 2021. In India alone, 31.8 million people were diagnosed with COVID-19 with a case fatality rate of 1.44%. [1] As the pandemic continues to progress, most countries from South Asia to Europe have seen a more severe second wave. [2] While data on reported cases, deaths, and testing drive the short-term management of the pandemic, given the high rate of asymptomatic infection in the population [20] that may go undetected, it is important to estimate active infection and seroprevalence in the general population for better matching of public health responses to the actual state of the pandemic. Evidence from nationwide surveys in India, conducted by the Indian Council of Medical Research (ICMR), reported that the antibodies to SARS-CoV-2 were detected in 0.73% population during May-June 2020 (first round) [13] , in 6.6% during August-September 2020 (second round) [14] as daily cases and deaths peaked in the country, and in 24.1% of adults surveyed and 27.2% of 10 to 17-year-olds surveyed during December 2020 -January 2021 (third round). [22] Maharashtra, Kerala, Karnataka, and Tamil Nadu reported the highest number of confirmed cases at the state level. [16] Seroprevalence varied from 0.13% in Kerala [7] in an early study ending 31 May 2020 to 31.6% in Tamil Nadu [12] in a study ending 30 November 2020. In the first round of the survey in Karnataka, the estimated total burden was 27.7% as of 16 September 2020 [17] , while a higher prevalence of 39.6% was reported in select households. [15] All states in India, including Karnataka, showed a decreasing trend from mid-October 2020 to January 2021. Further, studies have found declining IgG levels in the general population. [18] , [19] , [26] , [27] Therefore, it is important to assess the active infection and seroprevalence in the population periodically. Serial cross-sectional sentinel-based population surveys [17] , conducted at different time points, provide insights on the epidemiological trend of infection spread. The cross-sectional nature provides a snapshot of the state of the pandemic across the survey region. The sentinel nature enables rapid and easier implementation. The serial nature ensures high-quality data from the same locations and population segments for capturing trends. We conducted such a survey across Karnataka for the second time. Given the significant variation in IgG titres in the infected population [26] [27] [28] [29] [30] and the evidence of declining levels of IgG in the general population [18] [19] [31] , we also conducted a longitudinal We followed a protocol similar to the first round (Round 1) in September 2020 [17] to estimate the fraction of the population with active infection and IgG antibodies at the time of the survey. The study was conducted in all 30 districts of Karnataka and eight administrative zones of the Bengaluru metropolitan area. This subdivision led to a total of 38 units across the state. Health facilities were selected based on geographical representation, feasibility, ease of recruitment and were the same as in Round 1 [17] . Sampling frame: The study sampled three population groups: low-, moderate-, and high-risk groups. The low-risk group comprised pregnant women presenting for a regular check-up at the ante-natal care (ANC) clinic and attenders of patients coming to the outpatient department in the healthcare facilities. The moderate-risk group comprised people with high contact in the community, e.g., bus-conductors, vendors at the vegetable markets, healthcare workers, pourakarmikas (waste-collectors), and individuals in congregate settings (such as markets, malls, retail stores, bus stops, railway stations, and hotel staff). The high-risk group, or more appropriately the vulnerable group, comprised the elderly and persons with comorbid conditions. Sample size: For a margin of error of 0.05 and a 95% confidence level, taking design effect to be 3, assuming 32.3% prevalence, which is 5% more than the total burden estimated in Round 1, [17] the minimum required sample size was 1050 per unit [24] or 39,900 across the 38 units. The 1050 samples per unit were divided equally (350 each) among the three risk groups and were further divided equally among the risk sub-groups. We included all adults ≥18 years. We excluded those already diagnosed with SARS-CoV-2 infection, those unwilling to provide a sample for the test or consent, those who had received vaccination for COVID-19, and those who already participated in Round 1. Data collection: We obtained written informed consent from all participants prior to recruitment. We then collected the meta-data of all consenting participants (demographic details, comorbidities, and symptoms suggestive of COVID-19 in the preceding one month). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint Sample collection and lab tests: For the reverse transcription-polymerase chain reaction (RT-PCR) test, we collected nasopharyngeal/oropharyngeal swabs. We used the current ICMR protocol for sample collection, cold-chain transport, and laboratory analysis and tested them through the ICMR-approved testing network. For IgG antibody testing, we collected 4 ml of venous blood, centrifuged it, transported the serum to the laboratory while maintaining a cold chain, and detected SARS-CoV-2-specific IgG antibodies using a commercial, ICMR- A longitudinal study to assess the clinical sensitivity of the test kit, in view of antibody waning, was also conducted. Setting, sampling frame, and sample size: In Round 1, around 4582 out of 15939 participants from all units tested positive on at least one of the tests (the rapid antigen test, which was conducted in Round 1 but not in Round 2, the RT-PCR test, and the antibody test). Of these, 4420 participants from all risk groups with unambiguous meta-data were selected for the longitudinal study expecting that 10-20% would agree to participate. Exclusion criteria: We excluded those with a breakthrough infection (after Round 1), those that were vaccinated, and those that did not provide informed consent. Data collection, sample collection, and lab tests: We obtained written informed consent from all participants prior to the study. As indicated above, we collected 4 ml of venous blood from each consenting participant, centrifuged it, transported the serum to the laboratory while maintaining a cold chain, and detected SARS-CoV-2-specific IgG antibodies using the same ELISA-based test kit (Zydus-Cadila) [25] . The Institutional Ethics Committee (IEC) of the Indian Institute of Public Health -Bengaluru campus reviewed and approved the study (vide. IIPHHB/TRCIEC/174/2020) and the subsequent change of protocol to perform the longitudinal study (vide PHFI/IIPH- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint BLR/076/2020-21). We informed the participants of the purpose of the surveys, how the samples would be taken and requested them to respond to the screening questions. After obtaining informed consent, we noted basic demographic details, exposure history, symptoms observed in the previous month, and clinical history. Participants' test results were shared with them by the concerned healthcare facility. IgG prevalence was defined as the fraction of the sampled population with detectable IgG antibodies; active infection fraction was defined as the fraction of the sampled population who test positive on the RT-PCR test, and total prevalence of COVID-19 was defined as the fraction of the sampled population with either detectable IgG or active infection. For the estimation of IgG prevalence, active infection fraction, total prevalence, confidence intervals, and the odds ratios, we followed the method as outlined in [17] . For predicting IgG prevalence based on co-morbidities and other factors, we used logistic regression. The longitudinal study was used to estimate the clinical sensitivity of the ELISA kit. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint The statewide survey was carried out in 290 healthcare facilities spread across Karnataka from 25 January to 18 (15.5--19 .1), respectively. Thus, the total prevalence was higher among males than females and was higher among the elderly population when compared with those aged <30 years (Table 1) . The high-risk (vulnerable) segment of the population continued to be at higher risk (16.8% (15.5--18.1)), followed by the moderate risk (14.3% (13.1--15.6)), and then the low-risk population (11.2% (10.0--12.4)). In a reversal from Round 1, the rural population had is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; 14.8)); this is unadjusted for the excluded population due to lack of availability of fine-grained rural/urban case data (Table 1) . Across risk-subcategories, pregnant women had the least total prevalence (8.9% (7.3--10.5)), while bus-conductors/auto-drivers (16.5% (13.5--19.5)), people with co-morbidities (16.3% (14.5--18.2)), and the elderly (17.3% (15.4--19. 2)) had higher prevalence. Interestingly, pourakarmikas, who carry out work in less hygienic conditions, had a total prevalence of 14.8% (11.8--17.7) that did not stand out from the general population. Odds risk for detectable IgG antibodies: The odds for males was 1.22 as compared to females. Across age groups, the odds for the 30-39, 40-49, 50-59, and 60+ age groups, over the reference 18-29 age group, were 1.36, 1.74, 1.67, and 1.73, respectively. The vulnerable population in the high-risk category continued to have higher odds of 1.6 over the low-risk category. In contrast, the moderate-risk category had odds of 1.32 over the low-risk category. The elderly had higher odds of 2.14 over the reference pregnant women sub-category. The odds for the urban population were 0.89 as compared to the rural population. See Table 1 for confidence intervals. Pre-existing medical conditions: The seroprevalence of IgG antibodies was higher among those with more than one co-morbidity (19.1%), followed by those with one co-morbidity (15.1%). Those who reported having more than one symptom had a higher IgG prevalence (15.3%) than those with no symptoms (14.4%). At the state level, for every RT-PCR confirmed case, there were 12 infected individuals with detectable IgG levels ( Districts/unit variations across the state: The active infection fractions across all districts were estimated as 0.0% (with varying confidence intervals given in Table 3 ). Hence, the total prevalence is the same as the IgG prevalence, with minor expansions of the confidence is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. Table 1 ). The CIR ranged from 4-8 and the IFR from 0.11%--0.28% (Supplementary Table 1 ). Explanatory variables: Logistic regression indicated that the following factors led to a higher probability of a positive IgG test outcome: "Other" sex category, chronic renal disease, moderate-or high-risk category, attenders of outpatients, transport professionals (busconductors/auto-drivers), healthcare workers, and age 30 years and above (Supplementary Table 4 ). No significant association was observed between symptoms and the presence of IgG antibodies. The longitudinal study was done from 02 April to 11 May 2021. We collected 648 samples is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Dharwad's IFR, the highest, ranged from 0.24%--0.50%. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint Similar to the first round, our present study involves several district and state agencies: 290 healthcare facilities across all districts of Karnataka and the associated healthcare workers participated in the effort. Our study is further unique in jointly estimating active prevalence and IgG antibody prevalence. Despite the sentinel-based nature of the survey, our sampling frame attempted to overcome bias in the facility-based sampling frame by, for example, sampling from pregnant women coming for a regular check-up and sampling attendees of patients instead of the patients themselves [17] . Additionally, to account for IgG antibody waning, we conducted a longitudinal study for estimating the clinical sensitivity of the IgG ELISA kit, and this enabled an interval estimate of the total prevalence in the state. The estimated IgG prevalence at the end of Round 2 (15.6%) is remarkably lower than the estimated total infection of 27.7% (95% CI: 26.1-29.3) at the end of Round 1 (IgG prevalence 16 .8% (15.5-18.1)). [17] Tamil Nadu, a neighbouring state, also reported a reduction in March-April 2021 (23%) compared to October-November 2020 (31.6%). [35] Assuming the labcalibrated analytical sensitivity (92.2%) yields an under-estimate of the IgG prevalence in view of IgG level decline (Round 2 began 131 days after Round 1 and 98 days after the active cases peaked in the state). The ICMR third round study [22] took two approaches to handle antibody waningreduction in the optical density thresholds and an independent validation of the testing kitand reported the adjustments. We conducted an independent validation via a longitudinal study. The longitudinal study (conducted on a subset of the recalled Round 1 positive population) yielded a clinical sensitivity of ≥38.9% during the Round 2 period. The IgG ELISA test used the whole-cell antigen instead of the more specific recombinant nucleocapsid or spike protein antigens [25] . This, along with antibody waning, may have played a role in its reduced clinical sensitivity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint 26.1-37.7% (at 90% confidence), suggesting a significant level of susceptibility (and hence insufficient natural immunity) in the population as of 18 February 2021. The estimated active prevalence was 0.0% across all districts. The subsequent rise in infection from March to June 2021 may be due to a combination of effects ranging from immunity waning [23] to the emergence of the B.1.617 variant and its sub-variants. [37] Comparison of the CIR range 12--27 and IFR range 0.05--0.11% (Round 2) with CIR 40 and IFR 0.05% (Round 1) for Karnataka suggests improved case identification between Round 1 and Round 2. As in Round 1, Dharwad had the highest IFR (0.24%-0.50%). This could be due to reporting differences or issues related to clinical practice or travel from neighbouring units to avail critical or tertiary health care facilities at Dharwad. [17] Further research should explore these hypotheses. Males continued to be at higher risk than females (odds ratio 1.22), the vulnerable population in the high-risk category continued to be at higher risk than the low-risk category (odds ratio 1.6), those in the higher age groups continued to be at higher risk than the 18-29 age group (Table 1) . However, rural areas were more at risk than urban areas (odds ratio urban 0.89 < 1 rural), a reversal from Round 1. Together with the observations on antibody waning, the higher risk for rural areas suggests that the infection continued to be active in the rural areas after it had subsided in the urban areas during October 2020 -February 2021. Pregnant women are known to be more susceptible to respiratory pathogens, and hence to SARS-CoV-2, than the general population [36] . It is, therefore, reassuring to note that the total prevalence among pregnant women was the lowest, suggesting the hypothesis that their behavioural patterns result in significantly lower contact rates. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; higher CIR, suggesting the need to step up surveillance in those latter rural units (Belgaum, Kolar, Chamarajanagar, and Mandya). Finally, as in [17] , Figure 3 suggests a possible classification of districts into those with high/low CIR and high/low IFR. Districts with high CIR and low IFR in the top-left quadrant should consider re-evaluating their testing strategies and death reporting. As highlighted above, the sentinel-based population survey strategy has enabled the identification of trends over time. Such a survey is also easier to implement in terms of planning logistics for quick deployment. The study findings enable identifying districts that need better testing, reporting, or clinical management, all of which ultimately reduce the number of deaths due to COVID-19. Since the state was far from attaining natural immunity, vaccination coverage should be stepped up. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. We declare no competing interests. The data are accessible to researchers upon formal request for data addressed to the Commissioner, Health and Family Welfare Services, Government of Karnataka. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; coordinating and implementing the survey, for guiding the health facility and laboratory staff in sample collection, and for coordinating sample transportation to mapped RT-PCR and antibody testing labs. We thank the District Surveillance teams and ICTC teams in the districts for the collection and transportation of COVID-19 samples. We thank the Lab Nodal Officers and staffs of ICMR labs for IgG antibody testing and RT-PCR testing. We thank Dr Kousalya R of Institute of Nephro Urology (INU) for contributing in IgG testing of Sub study samples. We thank Mr Ramesh, Mr Mahesh and Mr SreeRam from IT Cell Admin, E-Health Division for providing a web platform for metadata collection. We thank Dr Sathyam for help with data analysis and validation. Our heartfelt gratitude goes to all the lab technicians, counsellors -ICTC & NCDC, staff nurses, and health workers for filling data in the survey app, collecting samples, and sending them to the mapped laboratories. We also thank the Institute of Nephro Urology for some preliminary testing of samples using an alternative IgG testing kit. We thank all the study participants for providing their consent to be a part of this survey. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 11, 2021. ; https://doi.org/10.1101/2021.08.10.21261842 doi: medRxiv preprint The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. The Lancet Patterns and persistence of SARS-CoV-2 IgG antibodies in a US metropolitan site Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults COVID Symptoms, Seroprevalence, and Mortality During the First Wave of SARS-CoV-2 in Canada Seroepidemiologische Studie zur Verbreitung von SARS-CoV-2 in der Bevölkerung an besonders betroffenen Orten in Deutschland-Studienprotokoll von CORONA-MONITORING lokal Technical paper COVID 19 Rapid Anti Body Test serosurveillance -Base line ReportKerala Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India-a crosssectional study Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study. medRxiv SARS-CoV-2 Seroprevalence in Tamil Nadu in Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey findings from the second nationwide household serosurvey. The Lancet Global Health Prevalence Of COVID-19 In Rural Versus Urban Areas in a Low-Income Country: Findings from a Statewide Study in Karnataka, India. medRxiv Ministry of Health and Family welfare GoI. Ministry of Health and Family welfare, Government of India The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults SARS-CoV-2 serological profile in healthcare professionals of a Southern Italy hospital Descriptive epidemiology of SARS-CoV-2 infection in Karnataka state, South India: Transmission dynamics of symptomatic vs. asymptomatic infections Predictive mathematical models of the COVID-19 pandemic: underlying principles and value of projections SARS-CoV-2 seroprevalence among the general population and healthcare workers in India Strategies to Mitigate COVID-19 Resurgence Assuming Immunity Waning: A Study for Karnataka, India. medRxiv COVID-19: Optimal Design of Serosurveys for Disease Burden Estimation Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. The Indian journal of medical research Neutralising antibody titres in SARS-CoV-2 infections Convergent antibody responses to SARS-CoV-2 in convalescent individuals Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population Antibody responses to SARS-CoV-2 in patients with COVID-19 Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 Special Correspondent to The Hindu. Sero-prevalence in T.N. stands at 23%. 23 Why are pregnant women susceptible to COVID-19? An immunological viewpoint Adjusted for sensitivities and specificities of RT-PCR, and antibody testing kits and procedures y Includes only samples that have been mapped to participants. @ All estimates are adjusted for sensitivities and specificities of the RT-PCR and antibody testing kits and procedures; the assumed values are RT-PCR sensitivity 0·95, specificity 0·97, IgG ELISA kit sensitivity 0·921, specificity 0·977; Weighted estimates for Karnataka estimate the prevalence in each unit and then weights according to population $ Markets, Malls, Retail stores, Bus stops, Railway stations, waste collectors; # Some individuals recruited in the moderate and low-risk categories, but with high risk-features, were moved to high-risk.